The nation of Zimbabwe has declined a significant US healthcare agreement worth $367m (£272m) over five years due to Washington's demand for sensitive biological samples.
This rejection came to light following a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
An official spokesman later explained that the United States was requesting biological samples for research and commercial gain but was not willing to guarantee the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate process of winding down our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more dialogue to secure a agreement agreeable to both sides so the nation's vital HIV treatment initiative can continue.
Wider Background
This development comes after a comparable situation in neighbouring Kenya, where a high court blocked a related health funding agreement after legal challenges were raised about the security of citizens' health data.
After resuming the presidency last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to boost transparency and accountability.
Based on reports, 16 African countries have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment via US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, without any corresponding guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"In essence, our country would supply the raw materials for scientific discovery without any certainty that the final treatments would be accessible to our citizens if a new health crisis emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending frameworks previously established through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to create them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage further dialogue with our American counterparts on how future collaboration might be designed in a manner that respects the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body expressed it acknowledged the government's concerns, but urged that talks should continue given that much of the nation's HIV programmes were funded by foreign aid.
"In cases where technical issues exist, such as those involving information security or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," the group commented.
This impasse underscores the complex challenges between receiving crucial foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.